EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

While platinum-based chemotherapy is the standard of care for the 1st line treatment of NSCLC with EGFR Exon20 insertion (Exon20ins) mutations, there is no consensus for further treatment once disease progresses. EGFR TKIs, anti-PD(L)1, anti-angiogenesis, among others, are frequently used. Sunvozertinib is a rationally designed EGFR Exon20ins inhibitor with wildtype selectivity. Results from the ongoing phase 1/2 studies showed sunvozertinib’s strong anti-tumor activity and benign safety profile.